RG7741

News alerts, weekly reports and conference planners

Company:

Pfizer, Roche

Drug class:

Chk1 inhibitor

Related drugs:

3years

GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2 Macrophage Infiltration in Mice. (PubMed, Onco Targets Ther)

Furthermore, we report a positive correlation between CHK1 expression and CCL2/CCR2 expression in the malignant tissues of patients with CRC. Taken together, we infer that GDC-0575 impairs the development of CAC and colitis by regulating cytokine expression and inhibiting CCR2 macrophage infiltration in mice colon.

3 years ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • IL1B (Interleukin 1, beta)

RG7741

4years

Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target. (PubMed, Clin Cancer Res)

This study suggests that apocrine features can be helpful in the identification of AA-responders. We identified Chk1 as a putative drug target in AR-positive TNBCs.

4 years ago

Clinical • Journal

AR (Androgen receptor)

AR positive

abiraterone acetate • RG7741